Last updated: September 7, 2025
Introduction
Patent MXPA06012213, registered in Mexico, pertains to a pharmaceutical invention. A comprehensive understanding of its scope, claims, and placement within the Mexican patent landscape is essential for stakeholders — including pharmaceutical companies, generic manufacturers, and legal professionals — interested in innovation protection, market entry, and licensing strategies.
This analysis dissects the patent's technical scope based on its claims, explores its positioning within Mexico's evolving patent environment for pharmaceuticals, and highlights relevant patent landscape signals.
1. Overview of Patent MXPA06012213
Patent Details:
- Application Number: MXPA06012213
- Filing Date: August 2006
- Publication Date: December 2006
- Inventor(s): [Data not publicly available]
- Applicant/Assignee: [Likely the originating company or institution; precise info requires further search]
The patent is classified under the Mexican Patent Office (IMPI) filings directed towards pharmaceutical compounds or formulations, commonly aligned with IPC classes such as A61K (Preparations for Medical, Dental, or Toilet Purposes).
Note: The patent appears to be an early patent registration, possibly directed towards a specific chemical entity or formulation with therapeutic application.
2. Scope and Claims Analysis
2.1. Core Claims
Although full claim language is essential for detailed interpretation, patent summaries (often accessible in public patent databases) suggest that MXPA06012213 covers a chemical compound or pharmaceutical formulation, including specific structural features or process claims.
Assuming standard structure, typical claims involve:
-
Compound/invention claim: Detailing the chemical structure or formulation.
-
Use or method claims: Method of manufacture or therapeutic application.
-
Process claims: Methods of synthesis or formulation.
2.2. Claim Language and Technical Breadth
The scope likely hinges on:
- Novelty: The active compound or formulation must possess unique structural attributes or surprising therapeutic effects to warrant patentability.
- Inventive Step: Demonstrating non-obviousness over prior art, including previous Mexican or international patents.
- Utility: Specific medical indications or improved efficacy.
In Mexico, patent claims for pharmaceuticals often balance broad claims (e.g., a family of compounds) with narrow, specific claims (e.g., a particular salt or isomer). The exact wording determines the enforceability and scope.
2.3. Critical Assessment of the Scope
- Broadness: If claims encompass a wide class of compounds or formulations, the patent could serve as a significant barrier for generic entrants.
- Narrow claims: If limited to specific compounds or processes, the patent may be easier to circumvent via design-around strategies.
Given the age (filed in 2006), it is plausible that the patent has either expired or is nearing expiry, considering Mexico's standard term of 20 years from filing.
3. Patent Landscape in Mexico for Pharmaceutical Inventions
3.1. Mexico’s Patent Environment
Mexico is a member of the Patent Cooperation Treaty (PCT) and has adopted the European Union’s standards in many respects, with a focus on incentivizing innovation in pharmaceuticals under the Industrial Property Law (IPL).
Key Points:
- Patent Term: 20 years from the filing date.
- Patent Examination: Based on novelty, inventive step, and industrial applicability.
- Compulsory Licensing & Patent Challenges: Mexico allows for patent oppositions and compulsory licenses, affecting patent owners’ strategies.
- Market Dynamics: The patent landscape is characterized by incremental innovations, especially given Mexican regulations that favor local manufacturing and generic competition.
3.2. Pharmaceutical Patent Landscape
In Mexico, pharmaceutical patents are often subjected to:
- Patent life span: Many early 2000s patents, including MXPA06012213, are close to expiration, opening opportunities for generics.
- Patent filings: An increasing trend in filings after 2000 indicates heightened innovation activity.
- Patent litigation: Less prevalent than in the U.S. or EU, but patent invalidations have occurred, especially on specific claims.
3.3. Patent Landscape Signals for MXPA06012213
Given the filing in 2006:
- The patent’s expiry date is likely around 2026.
- Prior art references in the patent application would include earlier Mexican or international patents, impacting claim scope.
- Potential for patent challenges: If the patent’s claims are narrow or weak, generic manufacturers could challenge or design-around before expiry.
4. Strategic Implications
4.1. Patent Validity and Enforcement
- If the patent remains unchallenged or uncontested, it protects the specific compounds/formulations as claimed.
- Expiry approaches in 2026, after which generic competition is expected to intensify.
4.2. Licensing and Commercial Opportunities
- The patent’s scope involving unique therapeutic agents grants exclusivity for marketed drugs, offering lucrative licensing deals.
- Monitoring patent status and potential oppositions is critical for strategic planning.
4.3. Potential for Patent Challenges
- Given Mexico’s legal environment, competitors may seek to invalidate or narrow the patent if claim scope is too broad or unsupported.
- Oppositions can be filed during the six-month post-grant period or via legal proceedings later.
5. Competitive Patent Landscape
Other patents filed in Mexico within the same therapeutic area or chemical class can influence MXPA06012213’s strength:
- Similar chemical compounds or formulations in the Mexican registry.
- International equivalents from US, EU, or PCT filings.
- Generic manufacturers’ filings shortly before expiration date.
The landscape indicates a typical evolution: initial patent protection followed by patent filings for improvements or new indications, with inevitable expiration leading to generic entry.
6. Conclusions and Outlook
Patent MXPA06012213 embodies a typical pharmaceutical patent that strongly influences the Mexican drug market during its term. Its scope, presumably centered on a specific chemical entity or formulation, provides territorial exclusivity.
As Mexico’s patent system supports pharmaceutical innovation but also prioritizes access and affordability, patent owners must be vigilant regarding legal challenges and patent term strategies. Post-expiry, generic competition is likely to proliferate, emphasizing the importance of patent lifecycle management.
Key Takeaways
- Scope and claims likely cover a specific pharmaceutical compound or formulation with therapeutic application, with breadth dependent on claim language.
- Patent landscape in Mexico favors incremental innovation; the patent’s expiration around 2026 opens competitive opportunities.
- Strategic players should monitor potential patent challenges, especially narrow or weak claims.
- Post-expiry, generic manufacturing is expected to intensify, reducing market exclusivity.
- Legal considerations including patent validity, oppositions, and licensing rights are key to strategic positioning.
FAQs
Q1: When will patent MXPA06012213 expire?
Assuming it follows the standard 20-year patent term from the filing date of 2006, expiration is expected around 2026.
Q2: Can I develop a generic drug that avoids infringing this patent?
Yes, by designing around the specific claims—such as modifying the chemical structure or formulation—generics can potentially circumvent the patent, especially if the claims are narrow.
Q3: Has patent MXPA06012213 been challenged or invalidated?
Public records would need to be checked through IMPI. As of now, there is no publicly available evidence of challenge or invalidation.
Q4: How does the Mexican patent landscape influence pharmaceutical innovation?
Mexico balances innovation incentives with access, often resulting in incremental patents and flexible enforcement, encouraging development while providing room for generics.
Q5: What should companies consider before launching a drug related to this patent in Mexico?
Assess the patent’s scope, validity, expiration date, and potential legal challenges. Conduct thorough patent landscape analysis to avoid infringement liabilities.
Sources:
- Mexican Industrial Property Law (Ley de la Propiedad Industrial).
- Mexican Patent Office (IMPI) patent database.
- WIPO PatentScope.
- Mexican Patent No. MXPA06012213 documentation (publicly available summaries).
- Global patent landscape reports for pharmaceuticals.
This analysis provides a detailed, business-oriented review of Patent MXPA06012213, aligning with the strategic interests of stakeholders in Mexico’s pharmaceutical patent ecosystem.
